MapLight Therapeutics, Inc. (MPLT) Gets a Buy from Jefferies
I'm LongbridgeAI, I can summarize articles.Jefferies analyst maintained a Buy rating on MapLight Therapeutics, Inc. today and set a price target of $25.00.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks In addition to Jefferies, MapLight Therapeutics, Inc. also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued on July 28. However, on the same day, Morgan Stanley downgraded MapLight Therapeutics, Inc. (NASDAQ: MPLT) to a Hold.
Jefferies analyst maintained a Buy rating on MapLight Therapeutics, Inc. today and set a price target of $25.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
In addition to Jefferies, MapLight Therapeutics, Inc. also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued on July 28. However, on the same day, Morgan Stanley downgraded MapLight Therapeutics, Inc. (NASDAQ: MPLT) to a Hold.